Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDKazia Therapeutics Limited Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 1 | -$0.01 | -$0.01 | -$0.01 |
Kazia Therapeutics Limited Earnings Date And Information
Kazia Therapeutics Limited last posted its earnings results on Friday, September 4th, 2026. The company reported $-0.60013 earnings per share for the quarter, topping analysts' consensus estimates of $-0.60547 by $0.0053399999999999. The company had revenue of 0 for the quarter and had revenue of 42.00 K for the year. Kazia Therapeutics Limited has generated $-19 earnings per share over the last year ($-18.9 diluted earnings per share) and currently has a price-to-earnings ratio of -1.44. Kazia Therapeutics Limited has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
Kazia Therapeutics Limited Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 03/19/2026 | Q2 2026 | N/A | -$3.95 | N/A | $0 | $0 |
| 11/07/2025 | Q4 2025 | -$0.01 | -$6.40 | -6.39 | $15.34 K | $19.71 K |
| 03/13/2025 | Q2 2025 | N/A | -$6.15 | N/A | N/A | $22.29 K |
| 11/15/2024 | Q4 2024 | N/A | -$31.20 | N/A | $149.71 K | $2.48 M |
| 12/30/2023 | Q2 2024 | N/A | -$18.40 | N/A | N/A | $5 |
| 10/26/2023 | Q4 2023 | N/A | -$15.10 | N/A | $90.31 K | $1.00 K |
| 03/09/2023 | Q2 2023 | N/A | -$46.65 | N/A | N/A | $0 |
| 10/17/2022 | Q4 2022 | N/A | -$44.40 | N/A | N/A | $0 |
| 12/31/2021 | Q2 2022 | N/A | -$50.00 | N/A | N/A | $10.00 K |
| 10/07/2021 | Q4 2021 | N/A | -$7.80 | N/A | N/A | $15.18 M |
| 12/30/2020 | Q2 2021 | N/A | -$29.60 | N/A | N/A | $1.17 K |
| 10/22/2020 | Q4 2020 | N/A | -$38.75 | N/A | N/A | $362.43 K |
| 12/31/2019 | Q2 2020 | N/A | -$43.05 | N/A | N/A | $625.68 K |
| 10/21/2019 | Q4 2019 | N/A | -$32.70 | N/A | N/A | $671.76 K |
| 12/31/2018 | Q2 2019 | N/A | -$54.60 | N/A | N/A | $768.24 K |
| 10/24/2018 | Q4 2018 | N/A | -$64.00 | N/A | N/A | $1.55 M |
| 12/31/2017 | Q2 2018 | N/A | $3.30 | N/A | N/A | $1.45 M |
| 10/25/2017 | Q4 2017 | N/A | -$64.35 | N/A | N/A | $4.20 M |
| 12/31/2016 | Q2 2017 | N/A | -$44.30 | N/A | N/A | $4.59 M |
| 10/27/2016 | Q4 2016 | N/A | -$91.75 | N/A | N/A | $236.09 K |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Kazia Therapeutics Limited Earnings: FAQ's
In the previous quarter, Kazia Therapeutics Limited (:KZIA) reported $-0.60013 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.60547 by $0.0053399999999999.
The conference call for Kazia Therapeutics Limited's latest earnings report can be listened to online.
The conference call transcript for Kazia Therapeutics Limited's latest earnings report can be read online.
Kazia Therapeutics Limited (:KZIA) has a recorded annual revenue of $42.00 K.
Kazia Therapeutics Limited (:KZIA) has a recorded net income of $-20,702,000.Kazia Therapeutics Limited has generated $-18.9 earnings per share over the last four quarters.
Kazia Therapeutics Limited (:KZIA) has a price-to-earnings ratio of -1.44 and price/earnings-to-growth ratio is -0.02.